Search - tctmd.com

Displaying 221 - 240 of 259

Sort: Relevancy | Date

News Industry News

Corvia Medical Completes Randomization In Reduce Lap-Hf II Pivotal Trial And Gains Fda Authorization To Provide Continued Access For The Corvia Atrial Shunt

November 17, 2020

News Daily News

Heart Failure Doubles Risk of Dying From COVID-19

L.A. McKeown

October 30, 2020

News Conference News HFSA 2020

Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study

L.A. McKeown

October 12, 2020

News Conference News HFSA 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

L.A. McKeown

October 09, 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2020

Shelley Wood

October 01, 2020

News Daily News

Recurrent Events After MI Show Enduring Gender, Racial Gaps in Care

Shelley Wood

September 22, 2020

News Conference News ESC 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

Todd Neale

August 30, 2020

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

News Daily News

Stick-on Sensor Predicts Heart-Failure Hospitalizations: Pilot Study

Shelley Wood

February 26, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Conference News AHA 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

Shelley Wood

November 22, 2019

Presentation Controversies and Advances 2019

Echo imaging in HFpEF

Presenter: Jeroen Bax

November 15, 2019

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

Presentation TCT 2019

Transcutaneous Pericardictomy for HFpEF

Presenter: Samuel Asirvatham

September 28, 2019

Presentation TCT 2019

Corvia for HFpEF

Presenter: Scott Lilly

September 28, 2019

Presentation TCT 2019

V-Wave for HFrEF and HFpEF

Presenter: Gregg Stone

September 28, 2019

Presentation TCT 2019

State of the Art: Latest Insights into the Pathophysiology and Medical and Device-Based Therapies for HFpEF

Presenter: Peter Carson

September 28, 2019

Presentation TCT 2019

Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator in Patients with HFrEF and HFpEF: The AFR-PRELIEVE Trial

Presenter: Felix Mahfoud

September 27, 2019

$Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction Primary results of the PARAGON-HF trial$

Presentation ESC 2019

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

Presenter: Scott D. Solomon

September 01, 2019

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

Todd Neale

September 01, 2019

Advertisement

Corvia Medical Completes Randomization In Reduce Lap-Hf II Pivotal Trial And Gains Fda Authorization To Provide Continued Access For The Corvia Atrial Shunt

Heart Failure Doubles Risk of Dying From COVID-19

Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

TCTMD’s Top 10 Most Popular Stories for September 2020

Recurrent Events After MI Show Enduring Gender, Racial Gaps in Care

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Stick-on Sensor Predicts Heart-Failure Hospitalizations: Pilot Study

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

Echo imaging in HFpEF

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

Transcutaneous Pericardictomy for HFpEF

Corvia for HFpEF

V-Wave for HFrEF and HFpEF

State of the Art: Latest Insights into the Pathophysiology and Medical and Device-Based Therapies for HFpEF

Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator in Patients with HFrEF and HFpEF: The AFR-PRELIEVE Trial

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content